Archive for the ‘british j of cancer’ Category
Last month, we brought you news that Pfizer had retracted a paper in the Journal of Clinical Oncology
purporting to show a benefit of their experimental drug for lung cancer figitumumab after discovering that its clinical lead on the project had done analyses improperly.
There’s been another retraction, of a related paper, in the British Journal of Cancer, “Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.” Here’s the notice: Read the rest of this entry »
The International Journal of Cancer, a Wiley title, has retracted a pair of articles from a group at UT Southwestern Medical Center in Dallas, for image manipulation.
The first was titled “Aberrant methylation of Reprimo in human malignancies.” According to the retraction notice: Read the rest of this entry »